Medical news
-
Update on Shire and Roche/Genentech patent dispute regarding Hemlibra
Update: On March 28, 2018, Chugai Pharmaceuticals, a subsidiary of Roche, announced that a Japanese court ruled that the hemophilia treatment product Hemlibra (emicizumab) does...
-
New and Updated: The Guide for the Assessment of Clotting Factor Concentrates, 3rd edition
Determining the safety and quality of therapeutic products for the treatment of hemophilia is crucial for the optimal treatment of patients. The World Federation of...
-
The WFH Compendium of Assessment Tools – The Toolbox for Hemophilia HCPs and Researchers
The World Federation of Hemophilia (WFH) Compendium of Assessment Tools-found on the WFH eLearning Platform-is an invaluable resource for researchers and healthcare professionals. A summary...
-
WFH Online Registry of Clotting Factor Concentrates
The Online Registry of Clotting Factor Concentrates on the World Federation of Hemophilia (WFH) eLearning Platform puts the details of over 100 products at your...
-
WBDR to go live this January
The World Federation of Hemophilia (WFH) World Bleeding Disorders Registry (WBDR) will go live with the enrollment of the first patient into the patient registry on...
-
WFH closely monitoring Shire and Roche/Genentech patent dispute
The World Federation of Hemophilia has been closely monitoring the developing situation between Shire and Roche/Genentech and their dispute over patent ownership. We will continue...
-
Update: FDA lifts suspension of Fitusiran trial
The United States Food and Drug Administration has agreed to allow Alnylam’s clinical trial of the novel drug Fitusiran to resume. The FDA and Alnylam...
-
Unmet needs and unfinished business in gene therapy
Three experts on gene therapy in hemophilia presented during the final session on day one of the 10th World Federation of Hemophilia Global Forum held...
-
Inhibitors: solving the problem
Three experts on inhibitors in hemophilia opened the first session of the 10th World Federation of Hemophilia (WFH) Global Forum held in Montreal on November...
-
FDA approves Hemlibra for treatment of hemophilia A with inhibitors
Roche has announced that the U.S.A Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for the treatment of hemophilia A with inhibitors. This approval...
